Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

Derosa, Giuseppe; Cicero, Arrigo F G; D’Angelo, Angela; Ragonesi, Pietro D.; Ciccarelli, Leonardina; Piccinni, Mario N.; Pricolo, Fabio; Salvadeo, Sibilla A T; Ferrari, Ilaria; Gravina, Alessia; Fogari, Roberto

doi:10.1291/hypres.29.849

Cited by 78 publications

(57 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further studies are needed to assess the effect of telmisartan on insulin resistance by hyperinsulinemic euglcyemic glucose clamp. It is noteworthy that other studies reported that telmisartan improves glycemic control and insulin sensitivity without affecting serum adi- (35)(36)(37). In rats fed a high-fat, high-carbohydrate diet, telmisartan treatment promoted increases in caloric expenditure and protected against dietary-induced weight gain (38).…”

Section: Discussionmentioning

confidence: 97%

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

et al. 2008

View full text Add to dashboard Cite

Olmesartan lowered mean systolic and diastolic blood pressure more significantly than did telmisartan.While there were no differences between the groups in metabolic parameters, including HbA1c and adiponectin, the decreases in serum interleukin-6 and highly sensitive C-reactive protein were more significant by olmesartan treatment. Our results indicate that olmesartan has more potent arterial blood pressure lowering and anti-inflammatory effects than telmisartan. (Hypertens Res 2008; 31: 7-13)

show abstract

Section: Discussionmentioning

confidence: 97%

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In fact, in a previous study comparing the effects of two different sartans (telmisartan and irbesartan) on adipokine levels, these effects actually did appear earlier with telmisartan than irbesartan. 40 Moreover, we did not evaluate the baseline distribution of adipose tissue in our patients, so we could not be sure that patients were equally distributed between the two treatment groups with regard to visceral adiposity. However, the patients were matched according to many anagraphic, clinical and metabolic parameters (including waist circumference and BMI), so we feel confident that the patients were adequately randomized.…”

Section: Discussionmentioning

confidence: 99%

Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients

et al. 2010

Self Cite

View full text Add to dashboard Cite

The aim of this study is to compare the effects of candesartan and olmesartan on insulin sensitivity-related parameters, before and after antihypertensive therapy. After a 4-week washout placebo period, 194 hypertensive (diastolic blood pressure (DBP) X80 mm Hg and systolic blood pressure (SBP) X130 mm Hg) patients with well-controlled type II diabetes were randomized to receive either 8 mg of candesartan once a day (o.d.) or 10 mg olmesartan o.d. and titrated after 1 month to 16 mg candesartan o.d. or 20 mg olmesartan o.d., respectively; the treatment period had a 1-year duration. We evaluated body weight, body mass index, SBP, DBP, glycated hemoglobin, fasting plasma glucose, M value, adiponectin (ADN), resistin (r), retinol-binding protein 4, visfatin, vaspin and high-sensitivity C-reactive protein (Hs-CRP) at their baseline values and after 6 and 12 months of treatment. We observed no variation in body weight or glycemic profile for either treatment. SBP and DBP were significantly reduced by both treatments (from 144 ± 8/88 ± 6 to 126 ± 5/77 ± 4 mm Hg by candesartan (Po0.001) and from 145 ± 9/89 ± 7 to 128 ± 7/79 ± 5 mm Hg by olmesartan (Po0.001)) without any difference between them. Retinol binding protein-4, r, and the vaspin value decreased in the candesartan group but not in olmesartan group. The M value, visfatin and ADN increased with candesartan, whereas no significant variations were observed with olmesartan. Both treatments resulted in a similar reduction in Hs-CRP. Although both therapies resulted in similar reductions in blood pressure, candesartan therapy was more effective than olmesartan therapy in improving insulin sensitivity. Keywords: adipokines; candesartan; olmesartan; type II diabetes mellitus INTRODUCTIONThe renin-angiotensin-aldosteron system (RAAS) is involved in a large number of physiopathological processes leading to hypertension and increased cardiovascular risk. Apparently, the principal mediator of such processes is angiotensin II (AII). 1 Evidence from animal models and cultured skeletal muscle cell line studies indicates that AII can induce insulin resistance, mediated by the impairment of insulin receptor substrate-1-dependent insulin signaling that is reversed by the administration of angiotensin receptor antagonism. 2 In addition, recent literature shows that AII is also strongly involved in adipose tissue metabolism. In fact, both angiotensin type 1 and 2 receptors have been localized to adipocytes, and differences in the regional expression of RAAS components in visceral vs. subcutaneous adipose tissue have been used to explain the link between abdominal obesity and cardiovascular disease. 3 Moreover, AII reduces the adipogenic response of adipocyte progenitor cells; the extent of this reduction correlates directly with the body mass index (BMI) of

show abstract

“…Although designed to bind to the AT1R, a subset of ARBs that includes telmisartan has the potential to activate the insulin-sensitizing nuclear hormone receptor PPAR γ, completely independent from their AT1R blocking properties. [25][26][27] Benson, et al 27) showed that the potent PPAR γ -activating ARB telmisartan improved insulin sensitivity in rats fed a high-fat diet, whereas losartan had no effect. In addition, they showed that adiponectin expression in adipocytes and fat tissue was solely up-regulated by PPAR γ -activating ARBs, whereas non-PPAR-activating ARBs had no effect.…”

Section: Discussionmentioning

confidence: 99%

Effects of ARB or ACE-Inhibitor Administration on Plasma Levels of Aldosterone and Adiponectin in Hypertension

et al. 2009

View full text Add to dashboard Cite

SummaryAldosterone production causes vascular injury and may occur despite the long-term administration of angiotensin converting enzyme-inhibitors (ACE-I) (ie, aldosterone breakthrough). The angiotensin II receptor blocker (ARB) telmisartan can function as a ligand for peroxisome proliferator-activated receptor (PPAR) γ. Stimulation of PPAR γ has been demonstrated to raise adiponectin production and suppress angiotensin II type 1 receptor expression. Thus, we investigated the effect of the ACE-I perindopril erbumin (perindopril) and the ARB telmisartan on plasma levels of aldosterone and adiponectin.Patients with essential hypertension were randomly assigned to receive 48 weeks of perindopril (2-8 mg/d) or telmisartan (20-80 mg/d). We measured adiponectin, aldosterone, angiotensin II, and renin at weeks 0, 8, 24, and 48.A total of 53 subjects were randomized. Data on 51 subjects (25 in the perindopril group and 26 in the telmisartan group; mean age, 65.1 years) were available for analyses. Plasma aldosterone decreased significantly in both the telmisartan (69.9 ± 5.6 to 58.1 ± 5.4 pg/mL) and perindopril (74.1 ± 4.7 to 64.7 ± 5.3 pg/mL) groups at 8 weeks, but returned toward the baseline in the perindopril group (67.9 ± 4.1 pg/mL) at 24 weeks. Plasma glycated hemoglobin levels or urine albumin did not change significantly after the treatment in either group.Telmisartan seemed to be more effective at suppressing aldosterone and raising adiponectin levels than perindopril; however, improvements in insulin sensitivity and albuminuria were not detected. These results are consistent with the idea that the use of an ARB with PPAR γ stimulating activity is equivalent to ACE-I for the treatment of hypertension. (Int Heart J 2009; 50: 501-512)

show abstract

Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

Cited by 78 publications

References 34 publications

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients

Effects of ARB or ACE-Inhibitor Administration on Plasma Levels of Aldosterone and Adiponectin in Hypertension

Contact Info

Product

Resources

About